Author:
Hua Le H,Bar-Or Amit,Cohan Stanley L,Lublin Fred D,Coyle Patricia K,Cree Bruce AC,Meng Xiangyi,Su Wendy,Cox Gina Mavrikis,Fox Robert J
Funder
Novartis Pharmaceuticals Corporation
Subject
Neurology (clinical),Neurology,General Medicine
Reference22 articles.
1. European Medicines Agency. Mayzent summary of product characteristics. 2020. Available from: https://www.ema.europa.eu/en/documents/product-information/mayzent-epar-product-information_en.pdf (Accessed November 24 2021).
2. Food and Drug Administration. Mayzent Prescribing Information. 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209884s000lbl.pdf (Accessed November 24 2021).
3. Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial;Arnold;Mult. Scler.,2022
4. Siponimod and cognition in secondary progressive multiple sclerosis: EXPAND secondary analyses;Benedict;Neurology,2021
5. Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?;Cerqueira;J. Neurol. Neurosurg. Psychiatry,2018
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献